Jessica Bean
Family · Clermont, FLNPI 1861876856
Payments from drug & device makers
Across 369 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$902
- AbbVie$810
- Lilly USA, LLC$468
- Bayer$453
- GSK$403
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,470100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 74 | $1,433 |
| AstraZeneca | 38 | $902 |
| AbbVie | 46 | $810 |
| Lilly USA, LLC | 28 | $468 |
| Bayer | 15 | $453 |
| GSK | 15 | $403 |
| Amgen | 23 | $374 |
| Pfizer | 16 | $288 |
| Sumitomo Pharma America, Inc. | 10 | $248 |
| Sanofi-aventis U.S. LLC | 12 | $225 |
| Astellas Pharma US Inc | 8 | $175 |
| Abbott | 8 | $168 |
| Johnson & Johnson | 9 | $144 |
| Organogenesis Inc. | 2 | $141 |
| Boehringer Ingelheim | 6 | $129 |
| Otsuka America Pharmaceutical, Inc. | 5 | $124 |
| Novartis | 7 | $114 |
| Dexcom, Inc. | 5 | $111 |
| Merck | 5 | $97 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Shield Therapeutics Inc | 4 | $73 |
| Amneal Pharmaceuticals LLC | 4 | $71 |
| Mylan Specialty L.p. | 3 | $66 |
| IBSA Pharma Inc. | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 4 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Averitas Pharma Inc. | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Biogen | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Corium, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Genentech USA, Inc. | 2 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125
- FARXIGA$125
- PuraPly$124
- TRELEGY ELLIPTA$122
How this compares
$7,470 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $163,831 |
| MounjaroTirzepatide | 69 | $93,277 |
| EliquisApixaban | 34 | $41,498 |
| Repatha SureclickEvolocumab | 41 | $27,608 |
| JardianceEmpagliflozin | 21 | $24,111 |
| JanuviaSitagliptin Phosphate | 14 | $22,843 |
| FarxigaDapagliflozin Propanediol | 30 | $22,778 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,704 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,256 |
| XareltoRivaroxaban | 12 | $9,150 |
| Atorvastatin Calcium | 241 | $1,945 |
| Levothyroxine Sodium | 228 | $1,924 |
| SynthroidLevothyroxine Sodium | 24 | $1,573 |
| Omeprazole | 124 | $1,524 |
| Valsartan | 54 | $1,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,433 | $163,831132 claims |
| Lilly USA, LLCMounjaro | $468 | $93,27769 claims |
| PfizerEliquis | $288 | $41,49834 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $902 | $34,48348 claims |
| Boehringer IngelheimJardiance | $129 | $24,11121 claims |
| MerckJanuvia | $97 | $22,84314 claims |
| GSKBreo Ellipta | $403 | $10,25626 claims |
| Johnson & JohnsonXarelto | $144 | $9,15012 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $71 | $1,924228 claims |
| AbbVieSynthroid | $810 | $1,57324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Clermont
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.